Clinical Trial Update: NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma [Phase 1]

View source ↗

Summary

A Phase 1 trial of NT-I7 in combination with nivolumab for advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• NT-I7
• nivolumab (nivolumab)

Snippet

Sponsor: NeoImmuneTech | Conditions: Gastric or Gastro-esophageal Junction (GEJ) or Esophageal Adenocarcinoma (EAC) | Phase 1 | Status: TERMINATED